New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ADI;CTRX;DISCA;EQIX;LBTYA;LMCA;REGN;SBAC;VRSK;WDC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
July 29, 2015
15:59 EDTSBAC, WDCNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Facebook (FB), consensus 47c... MetLife (MET), consensus $1.48... Williams (WMB), consensus 24c... Vertex (VRTX), consensus (58c)... O'Reilly Automotive (ORLY), consensus $2.26... NXP Semiconductors (NXPI), consensus $1.37... Marriott (MAR), consensus 81c... Fiserv (FISV), consensus 94c... Western Digital (WDC), consensus $1.45... SBA Communications (SBAC), consensus 9c... Whole Foods (WFM), consensus 45c... Lincoln National (LNC), consensus $1.53... Lam Research (LRCX), consensus $1.47... ServiceNow (NOW), consensus (2c)... Qorvo (QRVO), consensus $1.06... Hologic (HOLX), consensus 39c.
15:08 EDTWDC, SBACNotable companies reporting after market close
Subscribe for More Information
14:12 EDTWDCEarnings Watch: Hard drive makers report amid PC sector fears
Western Digital (WDC) and Seagate (STX) are expected to report quarterly results on July 29 and 31 with conference calls scheduled for 5:00 pm ET and 9:00 am ET, respectively. The two companies develop and manufacture computer storage solutions, including hard disk drives. EXPECTATIONS: Analysts are expecting Western Digital to report earnings per share of $1.45 on revenue of $3.25B, while Seagate is expected to report earnings per share of 64c on revenue of $2.92B. During its last earnings conference call, Western noted a "cautious" near-term outlook and forecast Q4 EPS to be $1.50-$1.60 on revenue of $3.3B-$3.4B. PRELIMINARY RESULTS: On July 13, Seagate reported preliminary Q4 revenue of $2.9B, adjusted gross margins of 27%, and 45M unit shipments, driven by what the company characterized as "lower than expected intra-quarter demand." The company had previously guided Q4 revenue to $3.2B-$3.3B, and analysts were looking for $3.19B in revenue at the time. LAST QUARTER: On April 17, Seagate reported Q3 adjusted EPS of $1.08 against expectations for $1.04, and revenue of $3.3B versus estimates of $3.4B. Following that, Western Digital reported Q3 EPS of $1.87 on April 28 versus estimates of $1.89, and revenue of $3.5B against expectations for $3.6B. NEWS: On May 1, Seagate announced plans to combine its Cloud Systems and Electronic Solutions groups, and on July 14, the company said it extended its alliance with HP (HPQ). STREET RESEARCH: On May 15, RBC called Western Digital shares "compelling" due to multiple near-term positive catalysts, though Morgan Stanley said on May 19 that it was just "cautiously optimistic" on Western because of softened growth expectations for the general PC market. On May 28, Goldman Sachs called fears of PC weakness overdone and upgraded Western Digital to Buy, saying the company's increasingly enterprise-heavy mix gives it a healthy long-term profit forecast. On June 12, Longbow reported that its hard drive price checks were not quite as bad as it had feared, adding that Western Digital's guidance appears achievable while Seagate's forecast appeared at risk. Heading closer to earnings, Citi said on July 2 that it expects somewhat weak quarterly results for the two hard drive giants but recommended buying both Western Digital and Seagate shares on any perceived post-earnings weakness. Stifel somewhat echoed that point on July 8, saying investor sentiment seemed overly negative towards Western, with traders potentially underestimating the company's shift towards enterprise products. Note that on July 23, Morgan Stanley said its June CIO survey indicated incremental enterprise IT budget weakness, leading the research firm to downgrade Western Digital to Equal Weight and drop Seagate two notches to Underweight. On the M&A front, Susquehanna said on May 29 that SanDisk (SNDK) remained an attractive takeover target, with Western Digital looking like a likely buyer. However, RBC and CLSA both raised doubts on June 5 about the possibility of such a deal. PRICE ACTION: Shares of Western Digital are up 1.34% to $78.83 ahead of Wednesday's report, while Seagate is up 0.84% to $49.28.
July 28, 2015
16:28 EDTVRSKVerisk Analytics reports Q2 adjusted EPS 77c, consensus 66c
Subscribe for More Information
15:21 EDTVRSKNotable companies reporting after market close
Subscribe for More Information
09:28 EDTREGNRegeneron buyout talk to renew after collaboration, says Roth Capital
Subscribe for More Information
09:18 EDTREGNOn The Fly: Pre-market Movers
Subscribe for More Information
07:40 EDTREGNRegeneron cancer deal could be major value driver, says RBC Capital
Subscribe for More Information
07:23 EDTEQIXEquinix price target raised to $310 from $270 at RBC Capital
RBC Capital increased its price target on Equinix citing what it sees as strong results by other companies in its sector, the stabilization of forex trends in recent months., and potential savings from the company's TeleCity deal. RBC keeps an Outperform rating on Equinix.
05:27 EDTREGNRegeneron, Sanofi launch immuno-oncology collaboration
Subscribe for More Information
July 27, 2015
10:45 EDTREGNEsperion price target lowered to $40 from $55 at Chardan
Chardan analyst Gbola Amusa earlier today lowered his price target for Esperion Therapeutics (ESPR) to $40 saying the label for Regeneron's (REGN) Praluent label "reveals multiple negatives" for the company. The FDA has had a policy change by not approving broad use for Praluent, Amusa told investors in a research note. He adds that Esperion's ETC-1002's add-on LDL-lowering ability is "much more modest" than Praluent. The analyst says he has increased conviction in his Sell rating on Esperion.
09:28 EDTDISCADiscovery, Comcast reach long-term renewal agreement, Deadline reports
Subscribe for More Information
08:22 EDTREGNNews reports on Regeneron Praluent label inaccurate, says RBC Capital
Subscribe for More Information
08:19 EDTREGNRegeneron drug price well above estimate, says Leerink
Leerink points out the $14,600 annual price for Regeneron's Praluent is well above its estimate of $5,000. The firm says the broad label and price make Praluent a $15B opportunity in the U.S. It reiterates an Outperform rating on Regeneron.
07:40 EDTREGNEsperion price target lowered to $120 from $130 at Citi
Subscribe for More Information
July 24, 2015
16:00 EDTREGNRegeneron, Sanofi say the U.S. WAC price of Praluent is $40 per day
Subscribe for More Information
15:41 EDTREGNRegeneron reopens, down 1.8% to $546.61 after FDA approves Praluent
15:35 EDTREGNRegeneron to resume trading at 3:40 pm ET
Subscribe for More Information
15:27 EDTREGNEsperion likely to stay pressured until path for ETC-1002 clearer, says Barclays
Subscribe for More Information
15:25 EDTREGNRegeneron, Sanofi's cholesterol treatment Praluent gets FDA approval
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration approved Praluent Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 inhibitors. Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol. The effect of Praluent on cardiovascular morbidity and mortality has not been determined. Praluent is the first and only PCSK9 inhibitor approved in the U.S. and is available in two different doses- 75 mg and 150 mg. Both doses of Praluent are available in a single 1 milliliter injection delivered in a single-dose prefilled pen or syringe that patients self-administer every two weeks. The companies carefully considered the potential medical value that Praluent offers patients in determining the Wholesale Acquisition Cost. The U.S. WAC price of Praluent is $40 per day, $1,120 every 28 days, for both the 75 mg and 150 mg doses, making Praluent the lowest priced patient-administered monoclonal antibody therapy on an annualized basis. Actual costs to patients, payers and health systems are anticipated to be lower as WAC pricing does not reflect discounts or rebates. Out-of-pocket costs to patients will vary depending on insurance status and eligibility for patient assistance.
15:00 EDTREGNBroader label for PCSK9 drug positive for Regeneron, Amgen, says Deutsche Bank
Subscribe for More Information
14:44 EDTREGNEsperion slides after FDA assigns indication for rival cholesterol drug
Shares of Esperion Therapeutics (ESPR), a drug company focused on LDL-cholesterol lowering therapies, are sharply lower in afternoon trading after the FDA granted approval for the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 inhibitors. WHAT'S NEW: This afternoon, the FDA announced the approval of Praluent injection, which is a PCSK9 drug marketed by Sanofi (SNY) and Regeneron (REGN). Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol, the FDA indicated. The drug, like Esperion's ETC-1002, seeks to lower patients' cholesterol. PRICE ACTION: In afternoon trading, Esperion shares are down 12% to $84.21. The stock spiked as low as $81.50 immediately after the FDA made its announcement regarding Praulent. Meanwhile, Sanofi shares are fractionally higher and Regeneron shares are halted.
14:20 EDTREGNFDA approves Regeneron, Sanofi cholesterol-lowering treatment
The announced the approval of Praluent injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 inhibitors. Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol. Praluent is marketed by Sanofi-Aventis (SNY) and Regeneron (REGN). Shares of Regeneron remain halted.
14:06 EDTREGNRegeneron trading halted, pending news
08:45 EDTREGNRegeneron cholesterol treatment likely to be approved today, says Bernstein
Bernstein notes that today is the PDUFA day for Regeneron's (REGN) and Amgen's (AMGN) Praluent, which would be the first antibody approved for cholesterol treatment in the U.S. The firm expects the drug to be approved today. After surveying doctors on the drug, Bernstein finds that their attitudes towards it are "remarkably positive." The firm keeps an Outperform rating on Regeneron and a Market Perform rating on Amgen.
07:21 EDTREGNRegeneron, Sanofi say CHMP recommends Euro approval of Praluent treatment
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicine Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for the marketing authorization of Praluent, recommending its approval for use in certain adult patients with hypercholesterolemia. Praluent is an investigational fully human monoclonal antibody targeting PCSK9. The European Commission is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in late September. The CHMP opinion was based on the benefit-risk profile of Praluent, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show consistent, positive results in reducing LDL-C. The U.S. Food and Drug Administration has set a target action date of July 24 for the Biologics License Application of Praluent. The safety and efficacy of Praluent have not been fully evaluated by any other regulatory authority.
07:18 EDTREGNRegeneron and Sanofi's Praluent recommended for approval in Europe
Regeneron (REGN) and Sanofi (SNY) announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent, recommending its approval for use in certain adult patients with hypercholesterolemia. Praluent is an investigational fully human monoclonal antibody targeting PCSK9. The European Commission is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in late September.
07:16 EDTREGNFDA PDUFA Date for Regeneron and Sanofi BLA for Praluent is July 24, 2015
Subscribe for More Information
July 23, 2015
10:00 EDTWDCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:29 EDTWDCWestern Digital downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
July 22, 2015
14:51 EDTADIEarnings Watch: Qualcomm reports after speculations of potential breakup
Qualcomm (QCOM) is expected to report third quarter earnings after the close on July 22, with a conference call scheduled for 4:45 pm ET. Qualcomm is a maker of semiconductors and telecommunications equipment. EXPECTATIONS: Analysts are looking for earnings per share of 95c on revenue of $5.85B. EPS consensus ranges 90c-$1.05 on a revenue range of $5.59B-$6.08B, according to First Call. LAST QUARTER: On April 22, Qualcomm reported Q2 EPS of $1.40 against expectations for $1.33, and revenue of $6.89B versus estimates of $6.83B. The company also cut its FY15 EPS guidance to $4.60-$5.00 from $4.85-$5.05 and lowered projected revenue to $25B-$27B from $26.3B-$28B, saying it expects pressure in its semiconductor business due to customer shifts in the premium segment and a decline in Qualcomm's share at an unnamed large customer. NEWS: On May 8, Reuters reported that EU antitrust regulators asked Qualcomm's competitors how the company's licensing and business practices affect them, and on July 16, the European Commission confirmed two formal antitrust investigations of the company. On May 25, Qualcomm and Daimler (DDAIF) announced a strategic collaboration to develop connected car technology. Coming on the heels of Avago's (AVGO) May 28 agreement to acquire Broadcom (BRCM), Bloomberg quoted a source later that day as saying Qualcomm, Intel (INTC), Altera (ALTR), Analog Devices (ADI), Maxim Integrated (MXIM), Texas Instruments (TXN), and Microchip Technology (MCHP) are all considering their own M&A opportunities. Note that on June 1, Intel announced an agreement to acquire Altera. On June 23, Semiconductor Manufacturing International (SMI), Qualcomm, Huawei, and Imec announced the formation of a joint venture to focus on a type of 14 nanometer technology. More recently, the Wall Street Journal reported on July 20 that Qualcomm is "expected" to begin a comprehensive strategic review which may include the possibility of a breakup following pressure from "activist" shareholder Jana Partners, according to sources, adding that the move could be announced concurrent with Wednesday's earnings release. STREET RESEARCH: Following last quarter's earnings report, Exane BNP Paribas downgraded Qualcomm to Neutral from Outperform, while both Canaccord and Brean Capital lowered price targets for the stock after "disappointing" guidance. Meanwhile, Citi said it expects the company's chip business to recover in 2016 despite this "very bad year." On May 28, CLSA said it sees continued pressure on Qualcomm chipsets, potentially spurring the company to consider making an acquisition, and on June 2, Craig-Hallum noted that Skyworks (SWKS) would be a great fit for Qualcomm. On June 24, Summit Research called Applied Micro Circuits (AMCC) an "affordable" target for Qualcomm, with AMD (AMD) and Cavium (CAVM) also looking like potential takeover candidates. On June 29, Drexel Hamilton downgraded Qualcomm to Sell from Hold, citing expected price cuts. Lastly, following media reports on July 20 that Qualcomm could be weighing a breakup, Bernstein said that such a "dis-synergistic" split would likely destroy value rather than create it. PRICE ACTION: Shares of Qualcomm are down more than 1% to $64.37 in afternoon trading ahead of Wednesday's earnings report.
12:38 EDTDISCADiscovery to acquire controlling stake in Eurosport from TF1
Subscribe for More Information
12:35 EDTADIAnalog chip makers fall after Linear cites weak end market demand
Subscribe for More Information
10:01 EDTREGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:01 EDTADIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:28 EDTADIAnalog Devices downgraded to Hold from Buy at Drexel Hamilton
Subscribe for More Information
08:39 EDTREGNRegeneron initiated with a Market Perform at Northland
Northland analyst James Kuo started shares of Regeneron Pharmaceuticals with a Market Perform rating and $500 price target. Pointing out that shares are up 34% year-to-date and 80% year-over-year, Kuo prefers to watch the upcoming launch of Praluent from the sidelines.
July 21, 2015
16:19 EDTDISCADiscovery files automatic mixed securities shelf
12:47 EDTREGNPiper confident in Regeneron approval by Friday
After Amgen's (AMGN) Repatha received marketing authorization in Europe, making it the first of the anti-PCSK9 antibody to be approved worldwide, Piper Jaffray analyst Edward Tenthoff expressed confidence that Regeneron (REGN) and Sanofi's (SNY) anti-PCSK9 antibody Praluent will be approved by Friday's FDA action date. Tenthoff believes Praluent will eventually be a blockbuster drug, but anticipates the launch to be slow. He keeps a Neutral rating on Regeneron with a $484 price target.
10:01 EDTVRSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:01 EDTVRSKOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ASML (ASML) upgraded to Accumulate from Neutral at SNS Securities... Anacor (ANAC) upgraded to Buy from Neutral at Goldman... Artisan Partners (APAM) upgraded to Outperform from Neutral at Credit Suisse... Canadian National (CNI) upgraded to Buy from Hold at Canaccord... General Mills (GIS) upgraded to Outperform from Sector Perform at RBC Capital... Halliburton (HAL) upgraded to Accumulate from Neutral at Global Hunter... Harte-Hanks (HHS) upgraded to Outperform from Market Perform at BMO Capital... MDC Partners (MDCA) upgraded to Overweight from Neutral at Piper Jaffray... SABMiller (SBMRY) upgraded to Buy from Neutral at Nomura... Sanmina (SANM) upgraded to Neutral from Underperform at Longbow... Santander Mexico (BSMX) upgraded to Neutral from Sell at Goldman... Sherwin-Williams (SHW) upgraded to Buy from Neutral at Northcoast... Southwestern Energy (SWN) upgraded to Buy from Neutral at Global Hunter... Verisk Analytics (VRSK) assumed with an Outperform at Keefe Bruyette.
06:33 EDTVRSKVerisk Analytics assumed with an Outperform at Keefe Bruyette
Subscribe for More Information
05:53 EDTVRSKVerisk Analytics downgraded to Sell from Neutral at UBS
UBS analyst Alex Kramm downgraded Verisk Analytics to Sell saying the current valuation looks "stretched" at current levels. Kramm sees increased uncertainty from insurance industry pressures and the company's expansion into the energy vertical. The analyst cut Verisk's price target to $74 from $79.
July 20, 2015
17:18 EDTLMCAD. E. Shaw & Co reports 5.1% passive stake in Liberty Media
Subscribe for More Information
10:00 EDTDISCAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:19 EDTEQIXBofA/Merrill data center analyst holds an analyst/industry conference call
Subscribe for More Information
07:02 EDTDISCADiscovery downgraded to Hold from Buy at Pivotal Research
Pivotal Research downgraded Discovery to Hold based on valuation and lowered its price target to $35 from $39 based on an updated cost of capital.
July 17, 2015
07:50 EDTCTRXUnitedHealth, Catamaran deal will close earlier than expected, says UBS
Subscribe for More Information
July 16, 2015
13:53 EDTCTRXUnitedHealth price target raised to $135 from $115 at Cantor
Cantor Fitzgerald analyst Joseph France raised his price target for UnitedHealth shares to $135 to reflect the company's Q2 earnings upside and the acquisition of Catamaran (CTRX). France reiterates a Hold rating on stock.
09:33 EDTCTRXUnitedHealth does not expect Catamaran to contribute to earnings this year
Subscribe for More Information
06:26 EDTLBTYALiberty Global resumed with an Overweight at JPMorgan
Subscribe for More Information
July 15, 2015
10:01 EDTLBTYA, WDCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AGCO (AGCO) upgraded to Market Perform from Underperform at Wells Fargo... Anglo American (AAUKY) upgraded to Outperform from Neutral at Credit Suisse... Avis Budget (CAR) upgraded to Buy from Hold at Deutsche Bank... Brookfield Renewable (BEP) upgraded to Neutral from Underperform at Credit Suisse... CSX (CSX) upgraded to Outperform from Sector Perform at RBC Capital... Centene (CNC) upgraded to Buy from Hold at Jefferies... Commerce Bancshares (CBSH) upgraded to Market Perform at Raymond James... Entegris (ENTG) upgraded to Buy at Craig-Hallum... Guess (GES) upgraded to Market Perform from Underperform at Telsey Advisory... Hertz (HTZ) upgraded to Buy from Hold at Deutsche Bank... Iberdrola (IBDRY) upgraded to Buy from Hold at Societe Generale... Liberty Global (LBTYA) upgraded to Conviction Buy from Buy at Goldman... LinkedIn (LNKD) upgraded to Overweight from Equal Weight at Barclays... Lonmin (LNMIY) upgraded to Neutral from Sell at Goldman... Navient (NAVI) upgraded to Overweight from Equal Weight at Barclays... NetApp (NTAP) upgraded to Sector Weight from Underweight at Pacific Crest... Omnicom (OMC) upgraded to Outperform from Market Perform at Wells Fargo... PTC Therapeutics (PTCT) upgraded to Overweight from Neutral at JPMorgan... Panera Bread (PNRA) upgraded to Overweight from Underweight at Piper Jaffray... Primerica (PRI) upgraded to Strong Buy from Market Perform at Raymond James... Sands China (SCHYY) upgraded to Overweight from Equal Weight at Barclays... Seagate (STX) upgraded to Buy at Craig-Hallum... Western Digital (WDC) upgraded to Buy from Hold at Craig-Hallum... Wolseley (WOSYY) upgraded to Overweight from Neutral at JPMorgan.
08:59 EDTWDCWestern Digital upgraded to Buy at Craig-Hallum
As previously reported, Craig-Hallum upgraded Western Digital to Buy from Hold and maintained its $89 price target. The firm believes PC data points will improve in 2H and management remains committed to remain committed to returning cash flow to investors.
07:36 EDTWDCWestern Digital upgraded to Buy from Hold at Craig-Hallum
06:14 EDTLBTYALiberty Global upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use